Variables | Univariable | Multivariable | ||
HR (95% CI) | p | HR (95% CI) | p | |
Gender | ||||
Male | 1 | |||
Female | 1.01 (0.54 to 1.90) | 0.970 | ||
Age at follow-up | ||||
0–2 | 1 | |||
2–5 | 0.78 (0.37 to 1.66) | 0.511 | 0.74 (0.33 to 1.55) | 0.445 |
>5 | 0.68 (0.29 to 1.60) | 0.384 | 0.79 (0.33 to 1.91) | 0.603 |
WHO clinical stage at enrolment | ||||
1 or 2 | 1 | |||
3 or 4 | 1.52 (0.60 to 3.86) | 0.390 | ||
Immunodeficiency at enrolment | ||||
Mild | 1 | |||
Advanced/severe | 2.44 (0.73 to 8.09) | 0.144 | 2.74 (0.78 to 9.68) | 0.117 |
z-Score (height for age) at enrolment | ||||
Mild | 1 | |||
Moderate/severe | 1.80 (0.96 to 3.39) | 0.068 | 1.84 (0.99 to 3.42) | 0.055 |
z-Score (weight for age) at enrolment | ||||
Mild | 1 | |||
Moderate/severe | 1.00 (0.51 to 1.96) | 0.098 | ||
z-Score (weight for height) at enrolment | ||||
Mild | 1 | |||
Moderate/severe | 1.20 (0.40 to 3.57) | 0.760 | ||
History of TB disease | ||||
No | 1 | |||
Yes | 0.83 (0.38 to 1.80) | 0.625 | ||
Cotrimoxazole/INH | ||||
Daily | 1 | |||
3 times a week | 0.89 (0.48 to 1.67) | 0.714 | ||
Placebo | 1 | |||
ART | 0.35 (0.07 to 1.63) | 0.179 | 0.32 (0.07 to 1.55) | 0.157 |
INH | 0.24 (0.11 to 0.55) | 0.001 | 0.22 (0.09 to 0.53) | 0.001 |
INH and ART | 0.14 (0.05 to 0.35) | <0.001 | 0.11 (0.04 to 0.32) | <00.01 |
ART, antiretroviral therapy; INH, isoniazid; TB, tuberculosis.